IN THE CLAIMS:

Please amend the claims to read as follows:

1.-82. (Cancelled)

83.   (Currently Amended) A method of assessing the effectiveness of a non-nucleoside reverse transcriptase inhibitor (NNRTI) on ~~an~~ a human immunodeficiency virus type 1 (HIV-1)-infected patient, comprising evaluating whether a plasma sample collected from the HIV-1-infected patient ~~contains a nucleic acid that has a mutation at codon 190 and codon 101 or 98, wherein the presence of the mutations at codon 190 and codon 101 or 98 is correlated~~ comprises encoding a reverse transcriptase (RT) that has one of the following mutations: G190A/S and K101E, or G190A/S and A98G, wherein said mutation is associated with increased susceptibility to delavirdine and decreased susceptibility to nevirapine and efavirenz.

84.   (Currently Amended) The method of claim 83, wherein the mutation at codon 190 encodes alanine (A) ~~or serine (S)~~.

85.   (Currently Amended) The method of claim 83, further comprising evaluating whether the nucleic acid encoding reverse transcriptase has an additional mutation ~~at codon 103~~ K103N, wherein the presence of the additional mutation in combination with the mutations ~~at codon 190 and codon 101 or 98~~ G190A/S and K101E, or G190A/S and A98G, is correlated with decreased susceptibility to delavirdine, nevirapine, and efavirenz.

86.   (Currently Amended) The method of claim ~~85~~83, wherein the mutation at codon ~~103~~ 190 encodes ~~asparagine (N)~~ serine (S).

87.-105. (Cancelled)